{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:50:53Z","timestamp":1793040653942,"version":"4.5.0"},"reference-count":241,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009374","name":"Amity Institute of Biotechnology, Amity University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001428","name":"Amity University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.micpath.2026.108545","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:29:00Z","timestamp":1778196540000},"page":"108545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Emerging therapeutic paradigms in tuberculosis: Nanocarriers, host-directed strategies, and translational pharmacology"],"prefix":"10.1016","volume":"216","author":[{"given":"Anjali","family":"Saxena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer","family":"Bhagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvayoo","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10481","key":"10.1016\/j.micpath.2026.108545_bib1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(24)02479-6","volume":"405","author":"Trajman","year":"2025","journal-title":"Tuberculosis. Lancet"},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pathogens12030362","article-title":"Management of tuberculosis infection: current situation, recent developments and operational challenges","volume":"12","author":"Agbota","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.micpath.2026.108545_bib4","article-title":"Clinical features, resistance patterns and treatment outcomes of drug-resistant extra-pulmonary tuberculosis: a scoping review","volume":"33","author":"Miiro","year":"2023","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/pharmaceutics13050592","article-title":"Recent progress and challenges for drug-resistant tuberculosis treatment","volume":"13","author":"Stephanie","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s12951-023-02156-y","article-title":"Advanced drug delivery and therapeutic strategies for tuberculosis treatment","volume":"21","author":"Nair","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s40001-025-02443-4","article-title":"Host-directed therapy for tuberculosis","volume":"30","author":"Tian","year":"2025","journal-title":"Eur. J. Med. Res."},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jac\/dkae429","article-title":"Efficacy of nintedanib as a host-directed therapy candidate in the treatment of tuberculosis","volume":"80","author":"Li","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2026.108545_bib9","first-page":"13","article-title":"Mycobacterium tuberculosis-macrophage interaction: molecular updates","author":"Bo","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2026.108545_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1572547","article-title":"Model systems to study Mycobacterium tuberculosis infections: an overview of scientific potential and impediments","volume":"15","author":"Nangpal","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"12","key":"10.1016\/j.micpath.2026.108545_bib11","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41579-025-01201-x","article-title":"Mycobacterium tuberculosis biology, pathogenicity and interaction with the host","volume":"23","author":"Warner","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/mi.2011.14","article-title":"Macrophages and control of granulomatous inflammation in tuberculosis","volume":"4","author":"Flynn","year":"2011","journal-title":"Mucosal Immunol."},{"issue":"7","key":"10.1016\/j.micpath.2026.108545_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/vaccines12070730","article-title":"Mycobacterium tuberculosis\u2013human immunodeficiency virus infection and the role of T cells in protection","volume":"12","author":"Hosseinian","year":"2024","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.micpath.2026.108545_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/eji.70004","article-title":"Granulysin antimicrobial activity promotes dormancy in Mycobacterium tuberculosis","volume":"55","author":"Schmidiger","year":"2025","journal-title":"Eur. J. Immunol."},{"issue":"13","key":"10.1016\/j.micpath.2026.108545_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310482","article-title":"Target identification in anti-tuberculosis drug discovery","volume":"24","author":"Capela","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"August","key":"10.1016\/j.micpath.2026.108545_bib16","article-title":"Activity of combinations of bactericidal and bacteriostatic compounds in mycobacterium abscessus-infected mice: an overview","volume":"16","author":"Lanni","year":"2025","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00232-021-00179-w","article-title":"Recent insights into the structure and function of mycobacterial membrane proteins facilitated by Cryo-EM","volume":"254","author":"Bendre","year":"2021","journal-title":"J. Membr. Biol."},{"issue":"14","key":"10.1016\/j.micpath.2026.108545_bib18","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1042\/BCJ20190324","article-title":"The Mycobacterium tuberculosis capsule: a cell structure with key implications in pathogenesis","volume":"476","author":"Kalscheuer","year":"2019","journal-title":"Biochem. J."},{"key":"10.1016\/j.micpath.2026.108545_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/9781683670131.ch65","article-title":"Unraveling the structure of the mycobacterial envelope","author":"Daff\u00e9","year":"2019"},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/pathogens12060839","article-title":"Virulence factors of Mycobacterium tuberculosis as modulators of cell death mechanisms","volume":"12","author":"Ramon-Luing","year":"2023","journal-title":"Pathogens"},{"issue":"7","key":"10.1016\/j.micpath.2026.108545_bib21","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/app10072278","article-title":"Mycobacterial cell wall: a source of successful targets for old and new drugs","volume":"10","author":"Vilch\u00e8ze","year":"2020","journal-title":"Appl. Sci."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12864-019-5615-3","article-title":"Genome-wide analysis of Mycobacterium tuberculosis polymorphisms reveals lineage-specific associations with drug resistance","volume":"20","author":"Oppong","year":"2019","journal-title":"BMC Genom."},{"key":"10.1016\/j.micpath.2026.108545_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1157559","article-title":"Editorial: evolution and genomics of the Mycobacterium tuberculosis complex","volume":"14","author":"Guimaraes","year":"2023","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s43556-022-00106-y","article-title":"The pathogenic mechanism of mycobacterium tuberculosis: implication for new drug development","volume":"3","author":"Yan","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.micpath.2026.108545_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1515627","article-title":"Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance\u2014India, 2018\u20132020","volume":"15","author":"Tamilzhalagan","year":"2025","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib26","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1038\/s41598-025-89087-w","article-title":"A comparative study of antibiotic resistance patterns in Mycobacterium tuberculosis","volume":"15","author":"Serajian","year":"2025","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.micpath.2026.108545_bib27","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.3390\/ijms25147771","article-title":"Mycobacterial biofilm: mechanisms, clinical problems, and treatments","volume":"25","author":"Liu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.353","article-title":"Mycobacterium tuberculosis : pathogenesis and therapeutic targets","volume":"4","author":"Yang","year":"2023","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009068","article-title":"Drug resistance gene mutations and treatment outcomes in MDR-TB: a prospective study in eastern China. Samy AM","volume":"15","author":"Liu","year":"2021","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108545_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.820134","article-title":"In the thick of it: formation of the tuberculous granuloma and its effects on host and therapeutic responses","volume":"13","author":"Cronan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1575133","article-title":"Microenvironments of tuberculous granuloma: advances and opportunities for therapy","volume":"16","author":"Krueger","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib32","article-title":"Progress of anti-tuberculosis drug targets and novel therapeutic strategies","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Microbiol."},{"issue":"8","key":"10.1016\/j.micpath.2026.108545_bib33","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1007\/s11033-021-06611-7","article-title":"Latent tuberculosis: interaction of virulence factors in Mycobacterium tuberculosis","volume":"48","author":"Sundararajan","year":"2021","journal-title":"Mol. Biol. Rep."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib34","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.21037\/jtd.2016.10.14","article-title":"Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives","volume":"8","author":"Rendon","year":"2016","journal-title":"J. Thorac. Dis."},{"issue":"11","key":"10.1016\/j.micpath.2026.108545_bib35","first-page":"1310","article-title":"Therapeutic strategies for tuberculosis: progress and lessons learned","volume":"37","author":"Sun","year":"2024","journal-title":"Biomed. Environ. Sci."},{"issue":"1184","key":"10.1016\/j.micpath.2026.108545_bib36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/postmj\/qgad140","article-title":"Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis","volume":"100","author":"Zhong","year":"2024","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.micpath.2026.108545_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107861","article-title":"Advances in the mechanisms of drug resistance of Mycobacterium tuberculosis","volume":"206","author":"Sikandar","year":"2025","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.micpath.2026.108545_bib38","series-title":"Clin Microbiol Rev","article-title":"The power of resistance: mechanisms of antimicrobial resistance in Mycobacterium tuberculosis and its impact on tuberculosis management","author":"Gopalaswamy","year":"2026"},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/ph14040323","article-title":"Antimicrobial peptides as potential anti-tubercular leads: a concise review","volume":"14","author":"Oliveira","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.micpath.2026.108545_bib40","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/molecules30071529","article-title":"Advances in antimicrobial peptides: mechanisms, design innovations, and biomedical potential","volume":"30","author":"Zhang","year":"2025","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/molecules30010128","article-title":"The role and mechanisms of antimicrobial peptides in overcoming multidrug-resistant bacteria","volume":"30","author":"Yang","year":"2024","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1021\/acsinfecdis.4c00806","article-title":"Decoding the role of antimicrobial peptides in the fight against Mycobacterium tuberculosis","volume":"11","author":"Saini","year":"2025","journal-title":"ACS Infect. Dis."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib43","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/ph18101440","article-title":"Peptide-based strategies against Mycobacterium tuberculosis covering immunomodulation, vaccines, synergistic therapy, and nanodelivery","volume":"18","author":"Roque-Borda","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s44368-024-00007-y","article-title":"Nano-strategies used for combatting the scourge of tuberculosis infections","volume":"1","author":"Fang","year":"2024","journal-title":"Discov. Immun."},{"key":"10.1016\/j.micpath.2026.108545_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111383","article-title":"Defensins: a novel weapon against mycobacterium tuberculosis?","volume":"127","author":"Gao","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib46","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s11095-023-03488-y","article-title":"Co-Delivery of D-LAK antimicrobial peptide and capreomycin as inhaled powder formulation to combat drug-resistant tuberculosis","volume":"40","author":"Shao","year":"2023","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib47","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12602-022-10018-6","article-title":"Antimicrobial peptides as immunomodulators and antimycobacterial agents to combat mycobacterium tuberculosis: a critical review","volume":"15","author":"Anbarasu","year":"2023","journal-title":"Probiotics Antimicrob. Proteins"},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10989-022-10435-9","article-title":"Role of antimicrobial peptides in treatment and prevention of mycobacterium tuberculosis: a review","volume":"28","author":"Mehta","year":"2022","journal-title":"Int. J. Pept. Res. Therapeut."},{"issue":"12","key":"10.1016\/j.micpath.2026.108545_bib49","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3390\/antibiotics11121772","article-title":"Cell-penetrating antimicrobial peptides with anti-infective activity against intracellular pathogens","volume":"11","author":"Cruz","year":"2022","journal-title":"Antibiotics"},{"issue":"35","key":"10.1016\/j.micpath.2026.108545_bib50","doi-asserted-by":"crossref","first-page":"20006","DOI":"10.1039\/D5NR00617A","article-title":"Cell-penetrating peptides as facilitators of cargo-specific nanocarrier-based drug delivery","volume":"17","author":"Jankowski","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.micpath.2026.108545_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1194923","article-title":"Mycobacterium tuberculosis cell-wall and antimicrobial peptides: a mission impossible?","volume":"14","author":"Jacobo-Delgado","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib52","article-title":"MicroRNAs as immune regulators and biomarkers in tuberculosis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib53","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.drudis.2021.01.021","article-title":"Interplay between miRNAs and mycobacterium tuberculosis: diagnostic and therapeutic implications","volume":"26","author":"Singh","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01139-20","article-title":"Inhibition of fatty acid oxidation promotes macrophage control of Mycobacterium tuberculosis","volume":"11","author":"Chandra","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.micpath.2026.108545_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106438","article-title":"MicroRNA-155, a double-blade sword regulator of innate tuberculosis immunity","volume":"185","author":"Abdalla","year":"2023","journal-title":"Microb. Pathog."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib56","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1038\/s41467-018-06836-4","article-title":"MicroRNA-27a controls the intracellular survival of Mycobacterium tuberculosis by regulating calcium-associated autophagy","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2026.108545_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.667206","article-title":"Monocyte and macrophage miRNA: potent biomarker and target for host-directed therapy for tuberculosis","volume":"12","author":"Sampath","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib58","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"10.1016\/j.micpath.2026.108545_bib59","first-page":"10","article-title":"The potential for microRNA therapeutics and clinical research","author":"Hanna","year":"2019","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib60","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1186\/s12951-024-02875-w","article-title":"Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy","volume":"22","author":"Liu","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib61","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/ph16101360","article-title":"Nanocarriers in tuberculosis treatment: challenges and delivery strategies","volume":"16","author":"Kumar","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.micpath.2026.108545_bib62","article-title":"Multifunctional nanocarrier systems for ampicillin delivery: comparative insights into polymer, lipid, mineral, and carbon-based platforms","volume":"115","author":"Pourmadadi","year":"2026","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.micpath.2026.108545_bib63","article-title":"Green nanocarriers and biodegradable systems for sustainable drug delivery solutions","volume":"111","author":"shirzad","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib64","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12879-021-06428-6","article-title":"Adherence to TB treatment remains low during continuation phase among adult patients in northwest Ethiopia","volume":"21","author":"Gashu","year":"2021","journal-title":"BMC Infect. Dis."},{"issue":"14","key":"10.1016\/j.micpath.2026.108545_bib65","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1021\/acs.analchem.1c03462","article-title":"Do anti-tuberculosis drugs reach their Target?\u2500High-Resolution matrix-assisted laser desorption\/ionization mass spectrometry imaging provides information on drug penetration into necrotic granulomas","volume":"94","author":"Kokesch-Himmelreich","year":"2022","journal-title":"Anal. Chem."},{"key":"10.1016\/j.micpath.2026.108545_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HMER.S290542","article-title":"Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia","volume":"13","author":"Molla","year":"2021","journal-title":"Hepatic Med."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00180-19","article-title":"The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives","volume":"35","author":"Dookie","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.micpath.2026.108545_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.749945","article-title":"Nanocarrier-based approaches for the efficient delivery of anti-tubercular drugs and vaccines for management of tuberculosis","volume":"12","author":"Rajput","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib69","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/10837450.2023.2279691","article-title":"Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs","volume":"28","author":"Ramachandran","year":"2023","journal-title":"Pharm. Dev. Technol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib70","article-title":"Rifabutin loaded inhalable \u03b2-glucan microparticle based drug delivery system for pulmonary TB","volume":"14","author":"Ahmad","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2026.108545_bib71","doi-asserted-by":"crossref","DOI":"10.1039\/D5PM00118H","article-title":"Spray-dried inhalable nano-embedded microparticles of isoniazid and pyridoxine hydrochloride for pulmonary tuberculosis","author":"Kole","year":"2026","journal-title":"RSC Pharm."},{"issue":"28","key":"10.1016\/j.micpath.2026.108545_bib72","doi-asserted-by":"crossref","first-page":"25515","DOI":"10.1021\/acsomega.3c03135","article-title":"Biopolymer-capped pyrazinamide-loaded colloidosomes: in vitro characterization and bioavailability studies","volume":"8","author":"Singh","year":"2023","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib73","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/02652048.2020.1857861","article-title":"Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation, ex vivo and in vivo assessment","volume":"38","author":"Shrivastava","year":"2021","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.micpath.2026.108545_bib74","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jconrel.2023.07.013","article-title":"Mycobacterial lipid-derived immunomodulatory drug- liposome conjugate eradicates endosome-localized mycobacteria","volume":"360","author":"Mishra","year":"2023","journal-title":"J. Contr. Release"},{"issue":"12","key":"10.1016\/j.micpath.2026.108545_bib75","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3390\/pharmaceutics13122041","article-title":"Application of lipid-based nanocarriers for antitubercular drug delivery: a review","volume":"13","author":"Buya","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2026.108545_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.mimet.2025.107138","article-title":"Current advancements in nanoparticles for vaccines and drug delivery for the treatment of tuberculosis","author":"Sharma","year":"2025","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.micpath.2026.108545_bib77","series-title":"Molecular Genetics of Mycobacteria","first-page":"411","article-title":"Molecular basis of drug resistance in Mycobacterium tuberculosis","author":"Cohen","year":"2015"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2091-11-35","article-title":"Molecular characterization of tlyA gene product, Rv1694 of mycobacterium tuberculosis: a non-conventional hemolysin and a ribosomal RNA methyl transferase","volume":"11","author":"Rahman","year":"2010","journal-title":"BMC Biochem."},{"issue":"7","key":"10.1016\/j.micpath.2026.108545_bib79","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/polym15071596","article-title":"Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems","volume":"15","author":"Yusuf","year":"2023","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.micpath.2026.108545_bib80","first-page":"1","article-title":"Mannosylated chitosan-decorated PLGA nanoparticles for targeted pulmonary delivery of isoniazid: a promising approach in the treatment of tuberculosis","author":"Maqbool","year":"2025","journal-title":"J. Drug Target."},{"issue":"4-S","key":"10.1016\/j.micpath.2026.108545_bib81","doi-asserted-by":"crossref","first-page":"249","DOI":"10.22270\/jddt.v12i4-S.5540","article-title":"A comprehensive review on sustained release matrix drug delivery system","volume":"12","author":"Kumar","year":"2022","journal-title":"J. Drug Deliv. Therapeut."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib82","article-title":"Nanotechnology\u2010based targeted drug delivery: an emerging tool to overcome tuberculosis","volume":"4","author":"Baranyai","year":"2021","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41579-020-0420-1","article-title":"Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections","volume":"19","author":"Makabenta","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib84","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.7150\/thno.38069","article-title":"Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics","volume":"10","author":"Mi","year":"2020","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib85","first-page":"77","article-title":"Stimuli-responsive nanocarriers for site-specific drug delivery system","volume":"8","author":"Gawai","year":"2020","journal-title":"Asian J. Pharmaceut. Res. Dev."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib86","doi-asserted-by":"crossref","first-page":"33","DOI":"10.33545\/26647222.2025.v7.i1a.148","article-title":"Emerging trends in osmotic pumps: a revolution in drug delivery systems","volume":"7","author":"Bhavija","year":"2025","journal-title":"Int. J. Pharm. Pharmaceut. Sci."},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib87","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/antibiotics11060806","article-title":"Adapting clofazimine for treatment of cutaneous tuberculosis by using self-double-emulsifying drug delivery systems","volume":"11","author":"van Staden","year":"2022","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib88","first-page":"959","article-title":"PP. Osmotic drug delivery system: a review","volume":"12","author":"Venkateswarlu\u2217","year":"2019","journal-title":"J. Drug Deliv. Therapeut."},{"issue":"19","key":"10.1016\/j.micpath.2026.108545_bib89","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib90","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/microorganisms13040722","article-title":"Innovative strategies for combating multidrug-resistant tuberculosis: advances in drug delivery systems and treatment","volume":"13","author":"Omoteso","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.micpath.2026.108545_bib91","series-title":"Novel Drug Delivery Systems","first-page":"235","article-title":"Implantable drug delivery systems","author":"Chamgordani","year":"2025"},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib92","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10544-019-0389-6","article-title":"Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases","volume":"21","author":"Pons-Faudoa","year":"2019","journal-title":"Biomed. Microdevices"},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib93","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/pharmaceutics15020393","article-title":"Nanosized drug delivery systems to fight tuberculosis","volume":"15","author":"Bourguignon","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib94","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1039\/D2BM01489K","article-title":"Nanocarriers for the delivery of antibiotics into cells against intracellular bacterial infection","volume":"11","author":"Wang","year":"2023","journal-title":"Biomater. Sci."},{"issue":"49","key":"10.1016\/j.micpath.2026.108545_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202506381","article-title":"Advancing tuberculosis chemotherapy: targeted nanomedicines for the mycobacterium TB granuloma","volume":"21","author":"Ranjith Singh","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.micpath.2026.108545_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.941077","article-title":"Recent advances in PLGA micro\/nanoparticle delivery systems as novel therapeutic approach for drug-resistant tuberculosis","volume":"10","author":"Shao","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"22","key":"10.1016\/j.micpath.2026.108545_bib97","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.3390\/polym13224036","article-title":"Recent advancement in chitosan-based nanoparticles for improved oral bioavailability and bioactivity of phytochemicals: challenges and perspectives","volume":"13","author":"Imam","year":"2021","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.micpath.2026.108545_bib98","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jddst.2019.05.025","article-title":"Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis","volume":"52","author":"Abdelghany","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib99","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/pharmaceutics16030429","article-title":"Mannose-decorated solid-lipid nanoparticles for alveolar macrophage targeted delivery of rifampicin","volume":"16","author":"Bera","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib100","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1039\/D2BM01835G","article-title":"Subcellular localization and therapeutic efficacy of polymeric micellar nanoparticles encapsulating bedaquiline for tuberculosis treatment in zebrafish","volume":"11","author":"Bhandari","year":"2023","journal-title":"Biomater. Sci."},{"issue":"7","key":"10.1016\/j.micpath.2026.108545_bib101","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1208\/s12249-018-1151-8","article-title":"Smartly engineered PEGylated Di-Block nanopolymeric micelles: duo delivery of isoniazid and rifampicin against Mycobacterium tuberculosis","volume":"19","author":"Rani","year":"2018","journal-title":"AAPS PharmSciTech"},{"issue":"9","key":"10.1016\/j.micpath.2026.108545_bib102","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1557\/s43580-023-00496-3","article-title":"Theragnostic liposomes for the diagnosis and treatment of tuberculosis","volume":"8","author":"Jim\u00e9nez-Rodr\u00edguez","year":"2023","journal-title":"MRS Adv."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib104","first-page":"661","article-title":"[Potential use of liposomes in tuberculosis treatment]","volume":"61","author":"Jacobo-Delgado","year":"2023","journal-title":"Rev. Med. Inst. Mex. Seguro Soc."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib105","first-page":"399","article-title":"Direct lungs targeting: an alternative treatment approach for pulmonary","volume":"15","author":"Vidyadevi","year":"2021","journal-title":"Tuberculosis"},{"key":"10.1016\/j.micpath.2026.108545_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2020.102008","article-title":"Solid lipid nanoparticles containing anti-tubercular drugs attenuate the Mycobacterium marinum infection","volume":"125","author":"Khatak","year":"2020","journal-title":"Tuberculosis"},{"issue":"12","key":"10.1016\/j.micpath.2026.108545_bib107","first-page":"1","article-title":"Lung-targeted solid lipid nanoparticles for enhanced pulmonary delivery of anti-tubercular drugs: a novel approach to improve bioavailability","volume":"8","author":"Paulami","year":"2024","journal-title":"J Angiother"},{"key":"10.1016\/j.micpath.2026.108545_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.nxnano.2025.100228","article-title":"Solid lipid nanoparticles based drug delivery for major infectious diseases: a narrative review","volume":"8","author":"Kumar","year":"2025","journal-title":"Next Nanotechnol."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib109","article-title":"Solid lipid nanoparticles (SLNPs): a state-of-the-art formulation strategy and their applications against tuberculosis (TB) and analgesic effects","volume":"15","author":"Mishra","year":"2025","journal-title":"Nanosci. Nanotechnol. - Asia"},{"key":"10.1016\/j.micpath.2026.108545_bib110","series-title":"Tubercular Drug Delivery Systems","first-page":"99","article-title":"Solid lipid nanoparticles in tuberculosis","author":"Rana","year":"2023"},{"key":"10.1016\/j.micpath.2026.108545_bib111","series-title":"Macrophage Targeted Delivery Systems","first-page":"399","article-title":"Macrophage-targeted chemotherapy for respiratory diseases other than tuberculosis","author":"Kohli","year":"2022"},{"issue":"11","key":"10.1016\/j.micpath.2026.108545_bib112","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2174\/0929867328666210629154908","article-title":"New perspectives in drug delivery systems for the treatment of tuberculosis","volume":"29","author":"da Silva Leite","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.micpath.2026.108545_bib113","doi-asserted-by":"crossref","DOI":"10.2174\/0122117385367493250224103839","article-title":"Nano drug delivery carriers (nanocarriers): a promising targeted strategy in tuberculosis and pain treatment","volume":"13","author":"Pal","year":"2025","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.micpath.2026.108545_bib114","article-title":"Nanocarriers for tuberculosis therapy: design of safe and effective drug delivery strategies to overcome the therapeutic challenges","volume":"67","author":"Sarkar","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.micpath.2026.108545_bib115","series-title":"Nanocarriers for Multidrug Resistant Tuberculosis (MDR TB) Therapy : a state-of-the-art Review","author":"Mandal","year":"2025"},{"key":"10.1016\/j.micpath.2026.108545_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.02930","article-title":"A nanostructured lipid system to improve the oral bioavailability of Ruthenium(II) complexes for the treatment of infections caused by Mycobacterium tuberculosis","volume":"9","author":"da Silva","year":"2018","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib117","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/pharmaceutics15041305","article-title":"Design, evaluation and comparison of nanostructured lipid carriers and chitosan nanoparticles as carriers of poorly soluble drugs to develop oral liquid formulations suitable for pediatric use","volume":"15","author":"Nerli","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2026.108545_bib118","doi-asserted-by":"crossref","DOI":"10.2174\/2210299X01666230508103042","article-title":"Development and characterization of linezolid loaded biocompatible solidlipid based nanocarrier for enhanced lung deposition and anti-tubercular activity: next generation tailor-made carrier for dry powder inhaler","author":"Kamble","year":"2023","journal-title":"Curr. Indian Sci."},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib119","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jbiosc.2021.08.009","article-title":"Inhalable nanoparticles delivery targeting alveolar macrophages for the treatment of pulmonary tuberculosis","volume":"132","author":"Chae","year":"2021","journal-title":"J. Biosci. Bioeng."},{"key":"10.1016\/j.micpath.2026.108545_bib120","article-title":"A review on recent advances in nanomedicines for the treatment of pulmonary tuberculosis","volume":"69","author":"Chaudhary","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib121","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40005-025-00729-7","article-title":"Current trends in inhaled pharmaceuticals: challenges and opportunities in respiratory infections treatment","volume":"55","author":"Shah","year":"2025","journal-title":"J. Pharm. Investig."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib122","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/1567201819666220812092556","article-title":"Dual rifampicin and isoniazid mannose-decorated lipopolysaccharide nanospheres for Macrophage- targeted lung delivery","volume":"20","author":"Sumaila","year":"2023","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.micpath.2026.108545_bib123","series-title":"Nanotechnology Based Approaches for Tuberculosis Treatment","first-page":"107","article-title":"Liposomes-and niosomes-based drug delivery systems for tuberculosis treatment","author":"Ibrahim Bekraki","year":"2020"},{"key":"10.1016\/j.micpath.2026.108545_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106484","article-title":"Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin","volume":"187","author":"Valverde-Fraga","year":"2023","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib125","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1038\/s41467-022-32043-3","article-title":"A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2026.108545_bib126","doi-asserted-by":"crossref","DOI":"10.2174\/0124681873413153251014082026","article-title":"Non-ionic surfactants (NIOs) in niosome drug delivery: in-depth review on clinical trials, patents in tuberculosis (TB) and oncology","volume":"16","author":"Koli","year":"2025","journal-title":"Curr. Nanomed."},{"key":"10.1016\/j.micpath.2026.108545_bib127","series-title":"Emerging Paradigms in Delivery Systems for Antitubercular Therapy","first-page":"281","article-title":"Recent approaches for the treatment of multidrug resistance tuberculosis","author":"Singh","year":"2025"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib128","article-title":"Niosomal as potential vesicular drug nano-carriers for the treatment of tuberculosis (TB)","volume":"15","author":"Pal","year":"2025","journal-title":"Nanosci. Nanotechnol. - Asia"},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib129","doi-asserted-by":"crossref","first-page":"218","DOI":"10.22270\/jddt.v14i3.6475","article-title":"Niosomal drug delivery system used in tuberculosis","volume":"14","author":"Shanker","year":"2024","journal-title":"J. Drug Deliv. Therapeut."},{"key":"10.1016\/j.micpath.2026.108545_bib130","article-title":"Dendrimers for drug delivery: an overview of its classes, synthesis, and applications","volume":"98","author":"Sarode","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib131","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s13346-020-00786-5","article-title":"Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention","volume":"10","author":"Nabi","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib132","doi-asserted-by":"crossref","first-page":"576","DOI":"10.2174\/187152711796235023","article-title":"Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain","volume":"10","author":"Beg","year":"2011","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"9","key":"10.1016\/j.micpath.2026.108545_bib133","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib134","article-title":"Clinically relevant metallic nanoparticles in tuberculosis diagnosis and therapy","volume":"8","author":"Akinnawo","year":"2025","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib135","doi-asserted-by":"crossref","DOI":"10.5001\/omj.2020.78","article-title":"The role of metallic nanoparticles in inhibition of Mycobacterium tuberculosis and enhances phagosome maturation into the infected macrophage","volume":"35","author":"Jafari","year":"2020","journal-title":"Oman Med. J."},{"key":"10.1016\/j.micpath.2026.108545_bib136","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2147\/IDR.S221408","article-title":"The anti-mycobacterial activity of Ag, ZnO, and Ag- ZnO nanoparticles against MDR- and XDR-mycobacterium tuberculosis","volume":"12","author":"Heidary","year":"2019","journal-title":"Infect. Drug Resist."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib137","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12951-023-02103-x","article-title":"Macrophage targeted iron oxide nanodecoys augment innate immunological and drug killings for more effective Mycobacterium tuberculosis clearance","volume":"21","author":"Shen","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"45","key":"10.1016\/j.micpath.2026.108545_bib138","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1039\/D3TB02292G","article-title":"Exploring the antimicrobial potential of isoniazid loaded Cu-based metal\u2013organic frameworks as a novel strategy for effective killing of Mycobacterium tuberculosis","volume":"11","author":"Kumar","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"12","key":"10.1016\/j.micpath.2026.108545_bib139","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/pharmaceutics11120687","article-title":"An inhalable theranostic system for local tuberculosis treatment containing an isoniazid loaded metal organic framework Fe-MIL-101-NH2\u2014From raw MOF to drug delivery system","volume":"11","author":"Wyszogrodzka-Gawe\u0142","year":"2019","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.micpath.2026.108545_bib140","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2174\/0115672018295247240426055330","article-title":"Applications of inorganic nanomaterials against tuberculosis: a comprehensive review","volume":"22","author":"Dastidar","year":"2025","journal-title":"Curr. Drug Deliv."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib141","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/17434440.2019.1671820","article-title":"Carbon nanomaterials: a new way against tuberculosis","volume":"16","author":"De Maio","year":"2019","journal-title":"Expert Rev. Med. Dev."},{"key":"10.1016\/j.micpath.2026.108545_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107379","article-title":"Macrophage targeted graphene oxide nanosystem synergize antibiotic killing and host immune defense for tuberculosis therapy","volume":"208","author":"Pi","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.micpath.2026.108545_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1395815","article-title":"Unraveling the potential of graphene quantum dots against Mycobacterium tuberculosis infection","volume":"15","author":"Santarelli","year":"2024","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib144","doi-asserted-by":"crossref","first-page":"15","DOI":"10.33263\/LIANBS141.015","article-title":"Nanotechnology-enabled biomaterials: transforming tuberculosis management through advanced diagnosis, targeted drug delivery, and immunotherapy","volume":"14","author":"Aparna Sharma","year":"2025","journal-title":"Lett. Appl. NanoBioSci."},{"key":"10.1016\/j.micpath.2026.108545_bib145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2024.11.063","article-title":"Stimuli-responsive mesoporous silica nanoplatforms for smart antibacterial therapies: from single to combination strategies","volume":"378","author":"Liao","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.micpath.2026.108545_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112384","article-title":"Selenium nanoparticles enhance mucosal immunity against Mycobacterium bovis infection","volume":"137","author":"Ge","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.micpath.2026.108545_bib147","first-page":"12","article-title":"Engineering zinc oxide hybrid selenium nanoparticles for synergetic anti-tuberculosis treatment by combining Mycobacterium tuberculosis killings and host cell immunological inhibition","author":"Lin","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"15","key":"10.1016\/j.micpath.2026.108545_bib148","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1039\/D4MA01224K","article-title":"Bactericidal activity of ZnO nanoparticles\u2013anti-TB drug combination towards the H37Rv strain and multidrug-resistant isolates of Mycobacterium tuberculosis via SufB splicing inhibition","volume":"6","author":"Ojha","year":"2025","journal-title":"Mater. Adv."},{"key":"10.1016\/j.micpath.2026.108545_bib149","article-title":"Antimycobacterial and antibacterial activity of green-synthesized silver and zinc oxide nanoparticles using Diospyros montana L. leaf extract","volume":"8","author":"Patil","year":"2025","journal-title":"Nanotechnology"},{"key":"10.1016\/j.micpath.2026.108545_bib150","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.actbio.2025.03.002","article-title":"cGAS-mediated antibacterial immunotherapy against tuberculosis by macrophage-targeted manganese dioxide nanoagonist","volume":"196","author":"Liao","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.micpath.2026.108545_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106132","article-title":"Zinc oxide nanoparticles have biphasic roles on mycobacterium-induced inflammation by activating autophagy and ferroptosis mechanisms in infected macrophages","volume":"180","author":"Geng","year":"2023","journal-title":"Microb. Pathog."},{"issue":"27","key":"10.1016\/j.micpath.2026.108545_bib152","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1039\/C9TB00784A","article-title":"Size-dependent antimycobacterial activity of titanium oxide nanoparticles against Mycobacterium tuberculosis","volume":"7","author":"Ramalingam","year":"2019","journal-title":"J. Mater. Chem. B"},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib153","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/nano13040767","article-title":"Titanium dioxide nanoparticles modulate systemic immune response and increase levels of reduced glutathione in mice after seven-week inhalation","volume":"13","author":"Lehotska Mikusova","year":"2023","journal-title":"Nanomaterials"},{"issue":"20","key":"10.1016\/j.micpath.2026.108545_bib154","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.3390\/nano13202803","article-title":"The impressive anti-inflammatory activity of cerium oxide nanoparticles: more than redox?","volume":"13","author":"Corsi","year":"2023","journal-title":"Nanomaterials"},{"key":"10.1016\/j.micpath.2026.108545_bib155","article-title":"Photothermal and host immune activated therapy of cutaneous tuberculosis using macrophage targeted mesoporous polydopamine nanoparticles","volume":"28","author":"Fan","year":"2024","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.micpath.2026.108545_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107219","article-title":"Development, characterization and evaluation of antibacterial efficacy of actively targeted gold-polydopamine nanoparticle formulations for tuberculosis treatment","volume":"213","author":"Turan-Ayhan","year":"2025","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib157","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70109","article-title":"Functionalized polydopamine nanoparticles: a promising drug delivery platform for the treatment of tuberculosis","volume":"86","author":"Okafor","year":"2025","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.micpath.2026.108545_bib158","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1010008","article-title":"Editorial: extracellular vesicles in diseases, host-pathogen interaction and therapeutic applications","volume":"12","author":"Alves","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib159","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/bacteria4040063","article-title":"Extracellular vesicles in host\u2013pathogen interactions: roles of exosomes and bacterial outer membrane vesicles in immunity and microbial communication","volume":"4","author":"Premchandani","year":"2025","journal-title":"Bacteria"},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib160","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255593","article-title":"Dynamin\u2010like proteins mediate extracellular vesicle secretion in Mycobacterium tuberculosis","volume":"24","author":"Gupta","year":"2023","journal-title":"EMBO Rep."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib161","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02552-23","article-title":"Extracellular vesicles in mycobacteria: new findings in biogenesis, host-pathogen interactions, and diagnostics","volume":"15","author":"Salgueiro","year":"2024","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib162","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12879-025-10474-9","article-title":"Identifying plasma exosome antigens as a potential diagnostic biomarker for tuberculosis disease","volume":"25","author":"Jiang","year":"2025","journal-title":"BMC Infect. Dis."},{"issue":"11","key":"10.1016\/j.micpath.2026.108545_bib163","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/microorganisms12112129","article-title":"Improved isolation optimizes downstream application of extracellular vesicles derived from Mycobacterium tuberculosis","volume":"12","author":"Wang","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.micpath.2026.108545_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.microb.2025.100520","article-title":"Exosomes and extracellular vesicles, potential tools in the effective management of tuberculosis infection","volume":"8","author":"Gor","year":"2025","journal-title":"Microbe"},{"issue":"May","key":"10.1016\/j.micpath.2026.108545_bib165","first-page":"1","article-title":"Current landscape of exosomes in tuberculosis development, diagnosis, and treatment applications","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib166","article-title":"Cargoes of exosomes function as potential biomarkers for Mycobacterium tuberculosis infection","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib167","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2147\/IJN.S395246","article-title":"Angiopep-2 modified exosomes load rifampicin with potential for treating central nervous system tuberculosis","volume":"18","author":"Li","year":"2023","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.micpath.2026.108545_bib168","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.18632\/aging.202854","article-title":"Exosomes derived from mycobacterium tuberculosis-infected MSCs induce a pro-inflammatory response of macrophages","volume":"13","author":"Liu","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.micpath.2026.108545_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2023.102359","article-title":"Characteristics of plasma exosomes in drug-resistant tuberculosis patients","volume":"141","author":"Wu","year":"2023","journal-title":"Tuberculosis"},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib170","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41565-024-01618-0","article-title":"Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles","volume":"19","author":"Li","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib171","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1039\/D2RA06888E","article-title":"Effects of morphology and size of nanoscale drug carriers on cellular uptake and internalization process: a review","volume":"13","author":"Zhang","year":"2023","journal-title":"RSC Adv."},{"issue":"23","key":"10.1016\/j.micpath.2026.108545_bib172","doi-asserted-by":"crossref","first-page":"10436","DOI":"10.1039\/D1NR00901J","article-title":"Imaging of nanoparticle uptake and kinetics of intracellular trafficking in individual cells","volume":"13","author":"Vtyurina","year":"2021","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib173","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12951-022-01343-7","article-title":"The interaction between nanoparticles and immune system: application in the treatment of inflammatory diseases","volume":"20","author":"Liu","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.micpath.2026.108545_bib174","series-title":"Nanotheranostics and Precision Oncology","first-page":"339","article-title":"Active and passive targeting of nanoparticles","author":"Butt","year":"2026"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib175","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s11671-018-2728-6","article-title":"Insight into cellular uptake and intracellular trafficking of nanoparticles","volume":"13","author":"Foroozandeh","year":"2018","journal-title":"Nanoscale Res. Lett."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib176","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/acs.biomac.9b00214","article-title":"Rifampicin nanoformulation enhances treatment of tuberculosis in zebrafish","volume":"20","author":"Trousil","year":"2019","journal-title":"Biomacromolecules"},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib177","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/gastro\/goz028","article-title":"C-type lectin receptor-mediated immune recognition and response of the microbiota in the gut","volume":"7","author":"Li","year":"2019","journal-title":"Gastroenterol. Rep."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib178","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/08830185.2020.1732958","article-title":"Phenotypically simple yet a mechanistically complex process","volume":"39","author":"Kumar","year":"2020","journal-title":"Int. Rev. Immunol."},{"issue":"June","key":"10.1016\/j.micpath.2026.108545_bib179","first-page":"1","article-title":"Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis coinfection","volume":"13","author":"Shah","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib180","series-title":"Tubercular Drug Delivery Systems","first-page":"235","article-title":"Niosomes in tuberculosis","author":"Patel","year":"2023"},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib181","doi-asserted-by":"crossref","first-page":"262","DOI":"10.22270\/jddt.v14i6.6651","article-title":"A comprehensive review on niosomes in drug delivery and recent advancements","volume":"14","author":"Teron","year":"2024","journal-title":"J. Drug Deliv. Therapeut."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib182","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/cancers11050640","article-title":"Active targeting strategies using biological ligands for nanoparticle drug delivery systems","volume":"11","author":"Yoo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.micpath.2026.108545_bib183","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.2147\/DDDT.S505682","article-title":"Mannosamine-engineered nanoparticles for precision rifapentine delivery to macrophages: advancing targeted therapy against mycobacterium Tuberculosis","volume":"19","author":"Luan","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.micpath.2026.108545_bib184","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jconrel.2022.07.040","article-title":"CD44 receptor targeted nanoparticles augment immunity against tuberculosis in mice","volume":"349","author":"Singh","year":"2022","journal-title":"J. Contr. Release"},{"issue":"6","key":"10.1016\/j.micpath.2026.108545_bib185","article-title":"Recent developments in drug delivery for treatment of tuberculosis by targeting macrophages","volume":"5","author":"Gairola","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.micpath.2026.108545_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237016","article-title":"PolySialic acid-nanoparticles inhibit macrophage mediated inflammation through siglec agonism: a potential treatment for age related macular degeneration","volume":"14","author":"Krishnan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.00286","article-title":"Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances","volume":"8","author":"Yeh","year":"2020","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib188","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s13346-018-00607-w","article-title":"Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy","volume":"9","author":"Maretti","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib189","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/pharmaceutics11100508","article-title":"The impact of lipid Corona on rifampicin intramacrophagic transport using inhaled solid lipid nanoparticles surface-decorated with a mannosylated surfactant","volume":"11","author":"Maretti","year":"2019","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib190","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/nano10030568","article-title":"In vivo biodistribution of respirable solid lipid nanoparticles surface-decorated with a mannose-based surfactant: a promising tool for pulmonary tuberculosis treatment?","volume":"10","author":"Truzzi","year":"2020","journal-title":"Nanomaterials"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib191","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/nano14010106","article-title":"Monocyte (THP-1) response to silver nanoparticles synthesized with Rumex hymenosepalus root extract","volume":"14","author":"Alvarez-Cirerol","year":"2024","journal-title":"Nanomaterials"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib192","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12951-019-0537-4","article-title":"Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles","volume":"17","author":"Wang","year":"2019","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.micpath.2026.108545_bib193","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.2147\/DDDT.S320119","article-title":"A novel folic acid receptor-targeted drug delivery system based on curcumin-loaded \u03b2-Cyclodextrin nanoparticles for cancer treatment","volume":"15","author":"Hong","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"issue":"7","key":"10.1016\/j.micpath.2026.108545_bib194","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3390\/biom15071008","article-title":"Hyaluronic acid in immune response","volume":"15","author":"Chrostek","year":"2025","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.micpath.2026.108545_bib195","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/antibiotics10080908","article-title":"Antituberculosis targeted drug delivery as a potential future treatment approach","volume":"10","author":"Mazlan","year":"2021","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib196","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4049\/jimmunol.1700713","article-title":"Role of CD44 in regulating TLR2 activation of human macrophages and downstream expression of proinflammatory cytokines","volume":"200","author":"Qadri","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib197","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejpb.2022.03.009","article-title":"Host cell targeting of novel antimycobacterial 4-aminosalicylic acid derivatives with tuftsin carrier peptides","volume":"174","author":"Borb\u00e1la Horv\u00e1th","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib198","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/ph16101428","article-title":"Functionalizing dendrimers for targeted delivery of bioactive molecules to macrophages: a potential treatment for Mycobacterium tuberculosis infection\u2014A review","volume":"16","author":"Sanhueza","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.micpath.2026.108545_bib199","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1568629","article-title":"The N-formyl peptide receptors: much more than chemoattractant receptors. Relevance in health and disease","volume":"16","author":"Napolitano","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib200","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71180-1","article-title":"Differential requirement of formyl peptide receptor 1 in macrophages and neutrophils in the host defense against Mycobacterium tuberculosis infection","volume":"14","author":"Nafiz","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib201","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3390\/microorganisms13051040","article-title":"Host-directed therapies based on protease inhibitors to control Mycobacterium tuberculosis and HIV coinfection","volume":"13","author":"Mandal","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.micpath.2026.108545_bib202","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1017\/erm.2024.29","article-title":"Unlocking the potential of miRNAs in detecting pulmonary tuberculosis: prospects and pitfalls","volume":"26","author":"Arya","year":"2024","journal-title":"Expert Rev. Mol. Med."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib203","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3390\/ijms26041621","article-title":"Advances in host\u2013pathogen interactions in tuberculosis: emerging strategies for therapeutic intervention","volume":"26","author":"Nasiri","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.micpath.2026.108545_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121893","article-title":"Insights into innovative therapeutics for drug-resistant tuberculosis: host-directed therapy and autophagy inducing modified nanoparticles","volume":"622","author":"Khoza","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib205","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1021\/acsinfecdis.4c00713","article-title":"Immunomodulatory nanoparticles induce autophagy in macrophages and reduce Mycobacterium tuberculosis burden in the lungs of mice","volume":"11","author":"Bekale","year":"2025","journal-title":"ACS Infect. Dis."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib206","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1038\/s41467-024-48588-4","article-title":"Mycobacterium tuberculosis suppresses host antimicrobial peptides by dehydrogenating L-alanine","volume":"15","author":"Peng","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2026.108545_bib207","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.mib.2020.01.011","article-title":"Mycobacterium tuberculosis pathogenicity viewed through the lens of molecular Koch's postulates","volume":"54","author":"Ramakrishnan","year":"2020","journal-title":"Curr. Opin. Microbiol."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib208","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.apsb.2025.03.011","article-title":"Overview of host-directed antiviral targets for future research and drug development","volume":"15","author":"Gu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.micpath.2026.108545_bib209","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436557","article-title":"Future applications of host direct therapies for infectious disease treatment","volume":"15","author":"Thom","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107130","article-title":"Host-directed therapies: old and new approaches for the treatment of infections","volume":"146","author":"Goletti","year":"2024","journal-title":"Int. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib211","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/ijms20020340","article-title":"The immune escape mechanisms of Mycobacterium tuberculosis","volume":"20","author":"Zhai","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.micpath.2026.108545_bib212","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00281-015-0531-3","article-title":"Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis","volume":"38","author":"Dorhoi","year":"2016","journal-title":"Semin. Immunopathol."},{"issue":"102","key":"10.1016\/j.micpath.2026.108545_bib213","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ado5951","article-title":"Immunopathology in human tuberculosis","volume":"9","author":"Scriba","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib214","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.742053","article-title":"Editorial: host-directed therapies for tuberculosis","volume":"11","author":"Costa","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"11","key":"10.1016\/j.micpath.2026.108545_bib215","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/pathogens11111291","article-title":"Host-directed therapies for tuberculosis","volume":"11","author":"Jeong","year":"2022","journal-title":"Pathogens"},{"issue":"5","key":"10.1016\/j.micpath.2026.108545_bib216","article-title":"Role of cytokines and inflammatory biomarkers in the pathogenesis of pulmonary tuberculosis","volume":"11","author":"Manfi","year":"2025","journal-title":"J. Contemp. Med. Sci."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib217","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/15548627.2021.1938912","article-title":"Tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival","volume":"18","author":"Ge","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.micpath.2026.108545_bib218","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1233630","article-title":"Macrophage targeted polymeric curcumin nanoparticles limit intracellular survival of Mycobacterium tuberculosis through induction of autophagy and augment anti-TB activity of isoniazid in RAW 264.7 macrophages","volume":"14","author":"Gupta","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108545_bib219","article-title":"An immunoregulator nanomedicine approach for the treatment of tuberculosis","volume":"11","author":"Yang","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.micpath.2026.108545_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114588","article-title":"Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis","volume":"162","author":"Ayodele","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.micpath.2026.108545_bib221","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/pharmaceutics17111459","article-title":"Advanced nanosystems and emerging therapies: innovations in tuberculosis treatment and drug resistance","volume":"17","author":"Sharma","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2026.108545_bib222","first-page":"106","article-title":"Breaking barriers: the potential of nanosystems in antituberculosis therapy","volume":"39","author":"Carnero Canales","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.micpath.2026.108545_bib223","first-page":"10","article-title":"The macrophage response to Mycobacterium tuberculosis and opportunities for autophagy inducing nanomedicines for tuberculosis therapy","author":"Maphasa","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib224","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1039\/D2RA06334D","article-title":"Macrophage-targeted nanoparticles mediate synergistic photodynamic therapy and immunotherapy of tuberculosis","volume":"13","author":"Tian","year":"2023","journal-title":"RSC Adv."},{"issue":"12","key":"10.1016\/j.micpath.2026.108545_bib225","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/vaccines12121335","article-title":"Advancements in nanoparticle-based adjuvants for enhanced tuberculosis vaccination: a review","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.micpath.2026.108545_bib226","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s11095-025-03889-1","article-title":"Inhalable N-Acetylcysteine-loaded lactose-coated PLGA nanoparticles for tuberculosis treatment","volume":"42","author":"Chaudhary","year":"2025","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib227","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00088-23","article-title":"Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments","volume":"36","author":"Suman","year":"2023","journal-title":"Clin. Microbiol. Rev."},{"issue":"10","key":"10.1016\/j.micpath.2026.108545_bib228","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acsnano.3c01664","article-title":"Amorphous drug nanoparticles for inhalation therapy of multidrug-resistant tuberculosis","volume":"17","author":"Rudolph","year":"2023","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib229","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s43168-025-00507-x","article-title":"Nanoparticle theranostics for respiratory diseases: advances and challenges in asthma, lung cancer, and tuberculosis","volume":"19","author":"Feyzbakhsh","year":"2025","journal-title":"Egypt J. Bronchol."},{"issue":"9","key":"10.1016\/j.micpath.2026.108545_bib230","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s13346-025-01861-5","article-title":"Formulation and clinical translation of inhalable nanomedicines for the treatment and prevention of pulmonary infectious diseases","volume":"15","author":"Ahmed","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.micpath.2026.108545_bib231","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2024.03.013","article-title":"Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis","volume":"369","author":"Campos Pacheco","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.micpath.2026.108545_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2025.128253","article-title":"Host-directed therapeutic for the treatment of Mycobacterium tuberculosis","volume":"299","author":"Mahajan","year":"2025","journal-title":"Microbiol. Res."},{"issue":"Suppl 1","key":"10.1016\/j.micpath.2026.108545_bib233","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.4103\/2212-5531.307123","article-title":"Advancing host-directed therapy for tuberculosis\/MDR-TB","volume":"10","author":"Meda","year":"2021","journal-title":"Int. J. Mycobacteriol."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib234","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s13346-022-01252-0","article-title":"Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system","volume":"13","author":"Liu","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib235","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","article-title":"Recent advances in extracellular vesicles for therapeutic cargo delivery","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.micpath.2026.108545_bib236","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.912831","article-title":"Extracellular vesicles in mycobacteria and tuberculosis","volume":"12","author":"Mehaffy","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.micpath.2026.108545_bib237","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3390\/ijms25042071","article-title":"Cell membrane-coated nanoparticles for precision medicine: a comprehensive review of coating techniques for tissue-specific therapeutics","volume":"25","author":"Fern\u00e1ndez-Borbolla","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.micpath.2026.108545_bib238","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103909","article-title":"Artificial intelligence in drug discovery: a new frontier in the fight against Mycobacterium tuberculosis","volume":"29","author":"Abavisani","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib239","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12929-023-00932-4","article-title":"The future of CRISPR in Mycobacterium tuberculosis infection","volume":"30","author":"Zein-Eddine","year":"2023","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib240","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.1038\/s41467-024-53637-z","article-title":"Genome-wide screen of mycobacterium tuberculosis-infected macrophages revealed GID\/CTLH complex-mediated modulation of bacterial growth","volume":"15","author":"Simwela","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2026.108545_bib241","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105599","article-title":"An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4+ T cell responses to enhance BCG-Induced protective immunity against Mycobacterium tuberculosis","volume":"113","author":"Lukeman","year":"2025","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.micpath.2026.108545_bib242","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2469333","article-title":"RNA vaccines: the dawn of a new age for tuberculosis?","volume":"21","author":"Li","year":"2025","journal-title":"Hum. Vaccines Immunother."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026002718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026002718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T11:14:05Z","timestamp":1779016445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401026002718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":241,"alternative-id":["S0882401026002718"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108545","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutic paradigms in tuberculosis: Nanocarriers, host-directed strategies, and translational pharmacology","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108545"}}